Medpolimerprom Group
Native name | Группа компаний «Медполимерпром» |
|---|---|
Romanized name | Gruppa kompaniy Medpolimerprom |
| Joint-stock company | |
| ISIN | 🆔 |
| Industry | Medical devices |
| Founded 📆 | 20 May 2016 |
| Founder 👔 | |
| Headquarters 🏙️ | , , Russia |
Area served 🗺️ | |
Key people | Alexey Borisov, general director Eugene Spector, former chairman of the board |
| Products 📟 | Disposable medical products and consumables made from polyvinyl chloride |
| Members | |
Number of employees | |
| 🌐 Website | [Lua error in Module:WikidataIB at line 665: attempt to index field 'wikibase' (a nil value). ] |
| 📇 Address | |
| 📞 telephone | |
Medpolimerprom Group, also rendered in English as Medpolymerprom Group (Russian: Группа компаний «Медполимерпром»; abbreviated MPP Group), is a Russian medical device company group based in Moscow. Its registered legal entity, AO GK MPP, was incorporated on 20 May 2016, with the registered activity of manufacturing medical instruments and equipment.[1]
The company became prominent in 2017 after the Russian Ministry of Industry and Trade included it as the only company in a government register of suppliers of disposable medical devices made from polyvinyl chloride (PVC). Inclusion in the register gave a supplier preferences in public procurement for certain medical consumables, including products used for ventilators, blood transfusion, cardiopulmonary bypass and plasmapheresis.[2][3]
Background
Public company databases list AO GK MPP as a Moscow-based joint-stock company with the full Russian name Aktsionernoye obshchestvo "Gruppa kompaniy "Medpolimerprom". Saby Profile states that the company has share capital of 1 million rubles, OGRN 1167746483783, INN 7703410814 and Alexey Borisov as general director.[1] Vademecum reported in 2017 that AO GK Medpolimerprom was owned by Borisov and businessman Eugene Spector, while Meduza reported, citing SPARK-Interfax, that 40 percent of the company's shares belonged to Borisov and 60 percent to an unnamed Russian citizen, and noted that Vademecum had identified the second shareholder as Spector.[2][3]
Meduza described the group as a newly created company that entered a market previously served by many Russian and foreign suppliers of medical plastic products. The investigation reported that the relevant Russian market had been estimated by participants at about 10 billion rubles per year.[3] English-language coverage of Spector's later criminal cases described him as a former chair of the board of Medpolymerprom Group, a medical equipment company.[4]
Government procurement register
In August 2017, the Russian government adopted new rules for state procurement of disposable medical devices made from PVC. According to Vademecum, companies seeking inclusion in the new register were required to have production in Russia, at least seven registration certificates for medical devices, at least seven patents for medical device components or parts, and at least 700 million rubles in medical device revenue over the preceding three years.[2]
The Ministry of Industry and Trade's register, announced in October 2017, contained only Medpolimerprom. The effect of the rules was that other suppliers could be removed from a tender if a registered company participated, under the Russian procurement principle often called the "third is superfluous" rule.[2][3] Vademecum also reported that Trading House Medpolimerprom had concluded 90 public procurement contracts for PVC medical devices worth more than 320 million rubles over the previous three years.[2]
The decision was criticized by other market participants. Vademecum reported that Viroban, a company that was not included in the register, asked the Russian prime minister to cancel the government resolution and reconsider the admission criteria.[5] Meduza's 2017 investigation described the rules as producing a de facto monopoly for Medpolimerprom in state purchases of the affected medical plastic products.[3]
Expansion plans
In November 2017, Vademecum reported that Medpolimerprom planned to build two production sites: one in Dubna for catheters and blood transfusion systems, and one in Yelets for infusion systems. Eugene Spector, then chairman of the board, estimated investment in the Moscow region project at 4 billion rubles, with production expected to start in 2019 to 2023. Vademecum reported that the Yelets production base had been under construction since 2015 with Mediko-proizvodstvennaya kompaniya Yelets, that Medpolimerprom had invested more than 980 million rubles into it, and that planned capacity was 36 million infusion systems a year.[5]
In July 2018, Kommersant reported that Medpolimerprom had been unable to begin construction of its planned Moscow region plant, whose investment had been estimated at 4 billion rubles. Spector told the newspaper that the company did not receive enough public orders to finance the project. Kommersant cited SPARK-Interfax data showing that Medpolimerprom signed public contracts worth 449 million rubles from January to July 2018, compared with 10.4 million rubles for all of 2017.[6]
Criminal cases involving former executives
Eugene Spector, the former chairman of the board of Medpolimerprom Group, was detained in 2020 in a bribery case involving Anastasia Alekseyeva, a former assistant to Russian deputy prime minister Arkady Dvorkovich. Interfax reported that in September 2022 Spector, after making a plea agreement with investigators, was sentenced to three and a half years in a strict regime penal colony for mediation in giving a bribe to Alekseyeva.[7]
In December 2024, the Moscow City Court sentenced Spector, a Russian-born U.S. citizen, to 15 years in a strict regime colony after convicting him of espionage. Interfax reported that the 15-year term was imposed by combining a 13-year espionage sentence with the earlier bribery conviction, and that the espionage trial was held behind closed doors because the case materials were classified.[7] Reuters reported that Russia's Federal Security Service later alleged that Spector had passed biotechnology and biomedical information to the United States; Reuters also noted that Spector had been chairman of the board of Medpolymerprom Group before his earlier arrest.[8]
See also
References
- ↑ 1.0 1.1 "ГК «ГК "МПП"» ИНН 7703410814, КПП 770301001, ОГРН 1167746483783 Москва". Saby Profile (in русский). Retrieved 12 June 2026.
- ↑ 2.0 2.1 2.2 2.3 2.4 "Госпоставщиком медизделий из ПВХ станет «Медполимерпром»". Vademecum (in русский). 12 October 2017. Retrieved 12 June 2026.
- ↑ 3.0 3.1 3.2 3.3 3.4 Zhegulyev, Ilya (1 December 2017). "Импортозаместитель". Meduza (in русский). Retrieved 12 June 2026.
- ↑ Timotija, Filip (24 December 2024). "Russian court sentences US citizen to 15 years in jail for espionage". The Hill. Retrieved 12 June 2026.
- ↑ 5.0 5.1 "«Медполимерпром» инвестирует в строительство двух заводов". Vademecum (in русский). 2 November 2017. Retrieved 12 June 2026.
- ↑ Kotova, Maria (13 July 2018). "Катетеры не дотянули до госзакупок". Kommersant (in русский). Retrieved 12 June 2026.
- ↑ 7.0 7.1 "Мосгорсуд приговорил к 15 годам колонии за шпионаж гражданина США Спектора". Interfax (in русский). 24 December 2024. Retrieved 12 June 2026.
- ↑ Osborn, Andrew (27 December 2024). "U.S. citizen jailed in Russia for 15 years leaked biotechnology secrets, FSB says". Reuters. Retrieved 12 June 2026.
This article "Medpolimerprom" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Medpolimerprom. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
